Netherlands-based Intravacc, a company active in translational research and development of viral and bacterial vaccines, has partnered with Buffalo, NY-based Therapyx, to further develop and optimize the world’s first prophylactic vaccine against gonorrhea, NGoXIM. For this Therapyx received a $2.8 million Phase IIB grant in the U.S. and has chosen to partner with Intravacc for its capabilities and infrastructure for the optimization of vaccines, vaccine processes and vaccine technologies....